Bharat Biotech Seeks Emergency Use Approval For Covaxin: Report

Earlier, the Serum Institute of India and Pfizer had sought approvals for their respective vaccine candidates. 

1 min read
Bharat Biotech, the company which is developing one of India’s indigenous vaccine candidates called Covaxin, said the vaccine will be at least 60% effective. 

Bharat Biotech, the Hyderabad-based pharmaceutical firm, has sought approval from Drugs Controller General of India (DCGI) for emergency use of its indigenously developed COVID-19 vaccine candidate – Covaxin, news agency PTI reported, citing sources.

The vaccine is being developed in collaboration with the Indian Council of Medical Research (ICMR) and is claimed to be at least 60 percent effective. Bharat Biotech had started the phase 3 trials earlier in November with 26,000 volunteers across 22 sites in India, making it the largest COVID-19 clinical trial in the country.

On Sunday, the Serum Institute of India (SII) became the first Indian company to seek emergency use authorisation for the Oxford COVID-19 vaccine from the central drug regulator.

Before that, the Indian arm of US pharmaceutical giant Pfizer had sought approval for its vaccine from DCGI, after the firm secured such clearance in the UK and Bahrain, PTI reported.

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!